Third Fund Dedicated to Life Science Investing PALO ALTO, CA – Prospect Venture Partners, a venture capital firm dedicated to investing in medical technology and life science companies, today announced the closing of its third fund, Prospect Venture Partners III. The oversubscribed fund was closed at $500 million. The majority of investors represented returning […]
Private equity interactive, Dow Jones Flush with a handful of exits this year, Prospect Venture Partners has raised $500 million for its third life sciences-focused fund, ahead of its $400 million goal. The new fund–which is the same size as its 2001 predecessor–would follow a similar strategy of investing in mainly early-stage biotechnology, biopharmaceutical […]
Prospect Venture Partners PALO ALTO, Calif., July 30 /PRNewswire/ — Prospect Venture Partners, a venture capital firm dedicated to investing in medical technology and life science companies, today announced the closing of its second fund, Prospect Venture Partners II. The oversubscribed fund was closed at $500 million. The fund’s four Managing Partners are Alex […]
Venture Capital & Health Care Journal Prospect Venture Partners, Palo Alto, has created a stir among health care investors by landing Dr. Russell C. Hirsch and Dr. James B. Tananbaum as general partners. The appointments do more than confirm that Prospect Venture Partners’ star is rising. They also illustrate how health care investors are benefiting […]